Spectrum Antimicrobials

Spectrum Antimicrobials is a biotechnology and pharmaceutical company specializing in infection-control solutions. The company has developed novel antiseptic and disinfectant formulations to combat viral, bacterial, fungal, and mold-caused infections in various bodily sites without leading to antibiotic resistance. Their platform technologies have the potential to significantly reduce the $30 billion spent annually in the US on antibiotic-resistant infections and over $80 billion on various strains of influenza. Moreover, their products could replace existing chemistries and therapies used for over 2 million bacterial infections and 40 million influenza cases100,000 patient deaths annually in the US. Founded in 2016 and headquartered in the United States, the company recently secured a $7.66M Venture Round investment on 01 April 2021.